The Enterprise Value as of September 2024 (TTM) for Ocular Therapeutix, Inc. (OCUL) is 923.38M

According to Ocular Therapeutix, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 923.38M. This represents a change of 90.00% compared to the average of 485.98M of the last 4 quarters.

Ocular Therapeutix, Inc. (OCUL) Historical Enterprise Value (quarterly & annually)

How has OCUL Enterprise Value performed in the past?

The mean historical Enterprise Value of Ocular Therapeutix, Inc. over the last ten years is 296.83M. The current 923.38M Enterprise Value has changed 31.01% with respect to the historical average. Over the past ten years (40 quarters), OCUL's Enterprise Value was at its highest in in the December 2020 quarter at 1.29B. The Enterprise Value was at its lowest in in the June 2016 quarter at 89.90M.

Ocular Therapeutix, Inc. (OCUL) Enterprise Value by Quarter and Year

Discovering the peaks and valleys of Ocular Therapeutix, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Ocular Therapeutix, Inc. (OCUL) Average Enterprise Value

How has OCUL Enterprise Value performed in the past?

The current Enterprise Value of Ocular Therapeutix, Inc. (OCUL) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

Ocular Therapeutix, Inc. (OCUL) Enterprise Value vs. Peers

How is OCUL’s Enterprise Value compared to its peers?

Ocular Therapeutix, Inc.’s Enterprise Value is greater than CytomX Therapeutics, Inc. (62.24M), greater than Assembly Biosciences, Inc. (90.35M), greater than Spero Therapeutics, Inc. (12.49M), greater than Achilles Therapeutics plc (-61068820.00), greater than Terns Pharmaceuticals, Inc. (458.36M), greater than Amylyx Pharmaceuticals, Inc. (89.50M), greater than Acumen Pharmaceuticals, Inc. (93.64M), greater than Inozyme Pharma, Inc. (343.89M), greater than X4 Pharmaceuticals, Inc. (40.79M), greater than Mereo BioPharma Group plc (582.99M), greater than PDS Biotechnology Corporation (74.53M), greater than HOOKIPA Pharma Inc. (87.25M), less than Day One Biopharmaceuticals, Inc. (1.01B),

Build a custom stock screener for Ocular Therapeutix, Inc. (OCUL) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Ocular Therapeutix, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Ocular Therapeutix, Inc. (OCUL) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Ocular Therapeutix, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.